ArticleEuropean journal of immunology2022
Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity.
Article in European journal of immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- Longitudinal Changes in IgG N-glycome Are Associated with Disease Severity and Mortality in COVID-19 Patients.Viruses · 2026Article
- Characterization of IgG N-glycan patterns in COVID-19, sepsis and healthy subjects.Scientific reports · 2026Article
- Immunoglobulin G N-glycosylation remodeling in viral infections: immunomodulatory roles and potential biomarker implications.Frontiers in immunology · 2026Review
- Rapid Glass Wool Enrichment of Glycopeptides for MALDI-MS Analysis of Immunoglobulin G Glycosylation in COVID-19 Samples.Journal of the American Society for Mass Spectrometry · 2025Article
- Soluble Factors and Mechanisms Regulated by Sialylated IgG Signaling.Immunological reviews · 2025Review
- Roles of core fucosylation modification in immune system and diseases.Cell insight · 2025Review
- Immunoglobulin GFrontiers in immunology · 2025Article
- Impaired mucosal IgA response in patients with severe COVID-19.Emerging microbes & infections · 2024Article
- A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogenic antibodies to mannose glycan.Nature immunology · 2024Article
- Infection and the Glycome─New Insights into Host Response.ACS infectious diseases · 2024Review
- Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection.Nature communications · 2024Article
- Control of complement-induced inflammatory responses to SARS-CoV-2 infection by anti-SARS-CoV-2 antibodies.The EMBO journal · 2024Article
- Complex changes in serum protein levels in COVID-19 convalescents.Scientific reports · 2024Article
- Host glycosylation of immunoglobulins impairs the immune response to acute Lyme disease.EBioMedicine · 2024Article
- IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition.Nature communications · 2024Article
- Role of Xenosialylation in Post-Infectious and Post-Vaccination Complications, Including Covid-19 and Anti-SARS-CoV-2 Vaccination.Journal of inflammation research · 2024Article
- Plasma Glycomic Markers of Accelerated Biological Aging During Chronic HIV Infection.bioRxiv : the preprint server for biology · 2023Article
- Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection.Cellular & molecular immunology · 2023Review
- Glycome dynamics in T and B cell development: basic immunological mechanisms and clinical applications.Trends in immunology · 2023Review
- ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.Nature immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear. Given the unpredictability for developing a severe/complicated disease, there is an urgent need in the field for predictive biomarkers of COVID-19. We have analyzed IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients, at diagnosis, by nano-LC-ESI-MS. We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis. We found that SARS-CoV-2+ individuals display, at diagnosis, variations in the glycans composition of circulating IgGs. Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease. Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course. This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.